Dr Sharman begins blogging on relevant ASCO pa... - CLL Support

CLL Support

23,253 members39,948 posts

Dr Sharman begins blogging on relevant ASCO papers

AussieNeil profile image
AussieNeilPartnerAdministrator
1 Reply

Dr Sharman blogged last Wednesday: "ASCO abstracts are out. It feels like Christmas Morning and I am 5 years old...".

Below are links to two of his recent blogs on this year's American Society of Clinical Oncology (ASCO) papers - both relevant to CLL treatment.

GA-101 aka. obinituzumab in CLL

Dr Sharman reports the big updates for this year and discovers something new from the report on the German three arm CLL11 study, in which chlorambucil was compared to chlorambucil in combination with either rituximab or GA-101.

"...the progression free survival went from 10 months with chlorambucil to 15 months with rituxan and 23 months with GA-101. To me that indicates that GA-101 is really doing something new / better than the stalwart rituximab."

cll-nhl.com/2013/05/ga-101-...

Ibrutinib Resistance

Read why Dr Sharman is excited about the paper "Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL)".

cll-nhl.com/2013/05/ibrutin...

Neil

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
1 Reply
splashsplash profile image
splashsplash

Thanks for the Xmas present Dr Sharman! I have to go in to hospital to discuss treatment options now my cells have started to come back in earnest, so this exciting information gives me hope.

Not what you're looking for?

You may also like...

Dr Sharman's thoughts on the race for FDA Approval for Obinituzumab, Ibrutinib and Idelalisib

Following Gilead's announcement regarding Idelalisib:...
AussieNeil profile image
Partner

Dr Sharman on "Choosing first therapy in CLL"

Dr. Sharman briefly discusses the whys of the rather unique Watch and Wait 'treatment' decision for...
AussieNeil profile image
Partner

Dr Sharman's latest post on preparing for and the experience of dying

An insightful and strangely reassuring post on the confronting but inevitable end for us all along...
AussieNeil profile image
Partner

ASH 2012 Interview: Dr Jeff Sharman "Why New CLL Treatments Supersede FCR"

Dr Sharman's blog http://www.cll-nhl.com, is well worth keeping an eye on for pertinent but easily...
AussieNeil profile image
Partner

Watch & Wait Article by Dr. Sharman

So a few key take home points 1) Watch and wait was historically based on ineffectiveness...
Cllcanada profile image
Top Poster CURE Hero